CA224|CA-224;CA 224

Cas No.:	883561-04-4
Chemical Name:	Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide
Synonyms:	CA-224;CA 224
SMILES:	C(C1=CC=CC=C1)1=CC=C(C(N(CCC2C3=C(NC=2)C=CC=C3)C)=O)C=C1
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A non-planar analogue of fascaplysin that selectively inhibits CDK4/cyclin D1 with IC50 of 5.5 uM; does not inhibits CDK2, blocks the growth of cancer cells at G0/G1 phase of the cell cycle, also blocks the cell cycle at G2/M phase; also acts as an enhancer of depolymerization for taxol-stabilized tubulin.

Cat. No.	Product name	Field of application
DC47707	CDK/HDAC-IN-1	CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC50 = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.
DC47706	CDK2-IN-7	CDK2-IN-7 is a CDK2 inhibitor for treating cancer (IC50 < 50 nM).
DC47705	JH-XVI-178	JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties.
DC47704	CDK9-IN-12	CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM.
DC47236	Cirtuvivint	Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research.
DC47205	Eltenac	Eltenac, a non-steroidal anti-inflammatory drug (NSAID), is a COX inhibitor. Eltenac shows IC50 of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood.
DC47130	CDK5-IN-1	CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research.
DC47109	Cimpuciclib	Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.
DC47043	Ocarocoxib	Ocarocoxib, a potent COX-2 (cyclooxygenase-2) inhibitor, is a non-steroidal anti-inflammatory for veterinary use.
DC46945	Avotaciclib	Avotaciclib (BEY1107) is an orally active cyclin dependent kinase 1 (CDK1) inhibitor. Avotaciclib can be used for the research of cancer.